Market Data graphic

Life Sciences

You are here

The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.

Life sciences companies listed on CSE

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 18 US jurisdictions and the EU. Columbia Care currently operates 100 facilities including 76 dispensaries and 24 cultivation and manufacturing facilities. Columbia Care is one of the original providers of medical cannabis in the United States, and continues to deliver an industry-leading, patient-centered medicinal cannabis operation that has quickly expanded into the adult use market as a premier operator. The company currently offers products spanning flower, edibles, oils, and tablets, and manufactures popular brands including Amber and Platinum Label CBD. With more than four million sales transactions since its inception in 2012, Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry.

 

CordovaCann Corp. is a Canadian-domiciled cannabis-focused consumer products company. CordovaCann primarily provides services and investment capital to the processing and production vertical markets of the cannabis industry.

Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.  The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

Cresco Labs also announced that it has entered into an agreement with a group of investment dealers, led by Canaccord Genuity Corp. (the “Underwriters”), pursuant to which the Underwriters will purchase, on a underwritten basis pursuant to the filing of a shelf prospectus supplement, an aggregate of 7,350,000 units (the “Units”) of the Company at a price of C$10.00 per Unit (the “Offering Price”) for aggregate gross proceeds of C$73,500,000 (the “Offering”).

Each Unit will be comprised of one subordinate voting share of the Company (a “Share”) and one half of one subordinate voting share purchase warrant of the Company (each full warrant, a “Warrant”). Each Warrant will entitle the holder to acquire one subordinate voting share of the Company (the “Underlying Shares”) at a price of C$12.50 per Underlying Share, subject to adjustment in certain events (the “Exercise Price”), for a period of 3 years following the Closing Date (as hereinafter defined). The Company intends to apply to list the Warrants on the Canadian Securities Exchange.

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco Labs is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco Labs’ national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

(Note: In addition to the 73,531,939 Subordinate Voting Shares that are issued and outstanding, there are 210,425,980 Subordinate Voting Shares reserved for issuance pursuant to the redemption and conversion rights attached to: (i) the outstanding Proportionate Voting Shares of Cresco Labs Inc. that are not listed,  and (ii) certain outstanding securities of Cresco Labs, LLC, which is a subsidiary of Cresco Labs, Inc. The total number of equity shares assuming all are converted into the listed class would be 281,703,424.)

 

Curaleaf Holdings, Inc., its subsidiaries and managed entities are directly engaged in the manufacture, possession, use, sale or distribution of cannabis and/or hold licenses in the adult-use and/or medicinal cannabis marketplace in the States of Arizona, Connecticut, Florida, Maine, Maryland, Massachusetts, Nevada, New Jersey, New York and Oregon.

Investor Note: In addition to the 590,281,217 Subordinate Voting Shares that are listed and trading, there are 93,970,705 shares reserved specifically for issuance pursuant to the conversion rights attached to the Multiple Voting Shares that are issued and outstanding but not listed. The total number of issued shares assuming all Multiple Voting Shares are converted into the listed class would be 684,251,922.

Discover Wellness (formerly RMMI Corp.) is a Canadian company licensed, through its subsidiary, to cultivate, produce, process and sell cannabis in various forms. The Company’s vision is to enhance shareholder value by establishing cost leadership in hemp processing and CBD extraction coupled with a global distribution strategy.

Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales in Canada and the United States.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.    

Contact The Team

How can we help you?

Contact the CSE team to find out more.

Advertisement

Publicité

Latest CSE News

Upcoming Events

2021-04-22-Earth-Day_Website.jpg

The CSE Celebrates: Earth Day!

Thursday, April 22, 2021 -
4:00pm to 5:00pm

Advertisement

Publicité